New frontiers in pediatric oncologic imaging

Cancer Imaging

Volumn 8, Issue 1, 2008, Pages 87-92

  McCarville, M Beth ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Contrast enhanced; Dynamic; Emission; Enhanced; Imaging; Magnetic; Positron; Resonance; Tomography; Tomography computed; Ultrasonography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; PERFLUTREN;

BONE MARROW BIOPSY; BONE SCINTISCANNING; BONE TUMOR; CHILDHOOD CANCER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG MONITORING; DRUG PENETRATION; ECHOGRAPHY; HUMAN; IMAGE ENHANCEMENT; INTERMETHOD COMPARISON; MUSCULOSKELETAL DISEASE; NEUROBLASTOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; RADIATION EXPOSURE; RADIOLOGIST; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR BLOOD FLOW; TUMOR VOLUME; VASCULAR TUMOR;

CHILD; DIAGNOSTIC IMAGING; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 41949104442     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2008.0012     Document Type: Review

References (23)

1. Fournier LS, Cuenod CA, Clement O, Siauve N, Frija G. Imaging of response to treatment in oncology. J Radiol 2007; 88: 829-43.
2. Frush DP, Donnelly LF, Rosen NS. Computed tomography and radiation risks: what pediatric health care providers should know. Pediatrics 2003; 112: 951-7.
3. Brody AS, Frush DP, Huda W, Brent RL. Radiation risk to children from computed tomography. Pediatrics 2007; 120: 677-82.
4. Provisor AJ, Ettinger LJ, Nachman JB et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 76-84.
5. Reddick WE, Wang S, Xiong X et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer 2001; 91: 2230-7.
6. Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology 1992; 184: 243-8.
7. Dyke JP, Panicek DM, Healey JH et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 2003; 228: 271-8.
8. Brenner W, Bohuslavizki KH, Eary JF. PET imaging of osteosarcoma. J Nucl Med 2003; 44: 930-42.
9. 18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005; 23: 8828-34.
10. Hawkins DS, Rajendran JG, Conrad EU, III, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 2002; 94: 3277-84.
11. McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol 2005; 184: 1293-304.
12. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19: 3397-405.
13. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
14. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
15. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 407-24.
16. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
17. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94: 883-93.
18. Padhani AR, Neeman M. Challenges for imaging angiogenesis. Br J Radiol 2001; 74: 886-90.
19. Anderson H, Price P, Blomley M, Leach MO, Workman P. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer 2001; 85: 1085-93.
20. Ferrara KW, Merritt CR, Burns PN, Foster FS, Mattrey RF, Wickline SA. Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. Acad Radiol 2000; 7: 824-39.
21. McCarville M, Streck C, Dickson PV, Li C-S, Nathwani A, Davidoff A. Quantitative, non-invasive assessment of intratumoral blood flow using contrast enhanced grayscale ultrasonography to evaluate the efficacy of angiogenesis inhibitors in a murine neuroblastoma model. Radiology 2006; 240: 73-81.
22. Dickson PV, Hamner JB, Sims TL et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942-50.
23. Dickson PV, Streck CJ, Ng CYC et al. Continuous delivery of interferon-beta promotes sustained intratumoral vascular normalization and tumor growth restriction through upregulation of angiopoietin-1. Mol Cancer Res 2007; 5: 531-42.